	US 12,269,870 B2
	Antigen binding regions against fibronectin type III domains and methods of using the same
Chichi Huang, Malvern, PA (US); John Lee, Ambler, PA (US); Jill Mooney, San Diego, CA (US); and Michael Naso, Swarthmore, PA (US)
Assigned to Janssen Biotech, Inc., Horsham, PA (US)
Filed by Janssen Biotech, Inc., Horsham, PA (US)
Filed on Oct. 4, 2021, as Appl. No. 17/493,032.
Application 17/493,032 is a division of application No. 16/037,340, filed on Jul. 17, 2018, granted, now 11,161,897.
Claims priority of provisional application 62/625,576, filed on Feb. 2, 2018.
Claims priority of provisional application 62/533,341, filed on Jul. 17, 2017.
Prior Publication US 2022/0127343 A1, Apr. 28, 2022
Int. Cl. A61K 48/00 (2006.01); A61P 35/00 (2006.01); C07K 16/18 (2006.01); C12N 15/10 (2006.01); C12N 15/62 (2006.01)

CPC C07K 16/18 (2013.01) [C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01)]

4 Claims

1. An isolated polynucleotide encoding a chimeric antigen receptor (CAR) comprising:

(a) an extracellular domain comprising an scFv comprising the amino acid sequence of SEQ ID NOs: 72 or 73, wherein the extracellular domain specifically binds to a non-randomized region of an FN3 domain;

(b) a transmembrane domain comprising the amino acid sequence of SEQ ID NO: 25; and

(c) an intracellular signaling domain comprising a co-stimulatory domain comprising the amino acid sequence of SEQ ID NO: 26, and a primary signaling domain comprising the amino acid sequence of SEQ ID NO: 27, wherein the CAR optionally further comprises a hinge region comprising the amino acid sequence of SEQ ID NO: 24 connecting the extracellular domain and the transmembrane domain.